{"id":745056,"date":"2023-04-04T08:27:24","date_gmt":"2023-04-04T12:27:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\/"},"modified":"2023-04-04T08:27:24","modified_gmt":"2023-04-04T12:27:24","slug":"eckert-ziegler-to-supply-point-biopharma-with-actinium-225","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\/","title":{"rendered":"Eckert & Ziegler to Supply POINT Biopharma with Actinium-225"},"content":{"rendered":"
\n

BERLIN and INDIANAPOLIS, April 04, 2023 (GLOBE NEWSWIRE) — Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (\u201cPOINT\u201d, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225 (non-carrier-added Ac-225). Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT\u2019s pipeline of next generation Ac-225-based radioligands.<\/p>\n

Actinium-225 is used as an active substance in cancer treatment. The radioisotope emits powerful, high-energy alpha particles with short penetration depths that enable precise treatment of tumor cells with minimal impact on surrounding healthy tissue. For this purpose, Actinium-225 is combined with a suitable carrier (e.g., an antibody or peptide) that specifically binds to cancer cells, thereby selectively targeting them. Clinical experts expect the demand for Actinium-225 to increase exponentially over the next decade. Eckert & Ziegler is currently developing a production process to be capable of supplying significant amounts of the highly demanded radionuclide Ac-225 to the market.<\/p>\n

\u201cThis contract once again underlines our leading position as a global supplier of high-quality theranostic radionuclides and we are very excited to be working with POINT Biopharma to support their radiopharmaceutical innovation,\u201d explained Dr. Harald Hasselmann, Executive Director and responsible for the Medical segment of Eckert & Ziegler. \u201cAs access to Actinium-225 is still very limited, we are happy to substantially improve this situation. With our own production we will become one of the first commercial suppliers to make the radioisotope available globally.\u201d<\/p>\n

\u201cSince our early days, POINT has placed a significant focus on radioligand manufacturing and isotope supply, two areas we believe have been overlooked by many in the industry,\u201d said Joe McCann, Ph.D., CEO of POINT Biopharma. \u201cThis agreement with Eckert & Ziegler contributes to our continued research and development with Actinium-225, an exciting therapeutic isotope. We are looking forward to launching our first Ac-225 phase 1 trial for the next generation PSMA-targeted PNT2001 program later this year.\u201d<\/p>\n

Besides Actinium-225, Eckert & Ziegler also supplies international pharmaceutical companies with Lutetium-177, Gallium-68, Yttrium-90 and other radioisotopes that are essential for use in diagnostics and therapy. In addition, the company offers contract development and manufacturing services for radiopharmaceuticals, including production for clinical and commercial phases, at three sites in Europe, North America, and Asia.<\/p>\n

\n About Eckert & Ziegler.<\/strong>
\n
Eckert & Ziegler Strahlen- und Medizintechnik AG with nearly 1,000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche B\u00f6rse.
Contributing to saving lives.<\/strong><\/p>\n

\n About POINT Biopharma Global Inc.<\/strong>
\n
POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT aims to transform precision medicine by combining a portfolio of targeted radioligand assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for medical isotopes including actinium-225 and lutetium-177. POINT\u2019s active clinical trials include FRONTIER, the phase 1 trial for PNT2004, a pan-cancer program targeting fibroblast activation protein-\u03b1 (FAP-\u03b1), and SPLASH, the phase 3 trial for PNT2002 for people with metastatic castration resistant prostate cancer (mCRPC) after second-line hormonal treatment. Learn more about POINT Biopharma Global Inc. at https:\/\/www.pointbiopharma.com\/.<\/p>\n

\n Contact<\/strong>
\n
Eckert & Ziegler AG
Robert-R\u00f6ssle-Str. 10, 13125 Berlin, Germany
Karolin Riehle, Investor Relations \/ Jan Sch\u00f6pflin, Marketing
karolin.riehle@ezag.de<\/a> \/ jan.schoepflin@ezag.de<\/a>
Tel.: +49 (0) 30 \/ 94 10 84-138; www.ezag.de<\/a><\/p>\n

\n Contact<\/strong>
\n
POINT Biopharma
Daniel Pearlstein
Associate Director, Corporate Strategy
investors@pointbiopharma.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BERLIN and INDIANAPOLIS, April 04, 2023 (GLOBE NEWSWIRE) — Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (\u201cPOINT\u201d, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225 (non-carrier-added Ac-225). Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT\u2019s pipeline of next generation Ac-225-based radioligands. Actinium-225 is used as an active substance in cancer treatment. The radioisotope emits powerful, high-energy alpha particles with short penetration depths that enable precise treatment of tumor cells with minimal impact on surrounding healthy tissue. For this purpose, Actinium-225 is combined with a suitable carrier (e.g., an antibody or peptide) that specifically binds to cancer cells, thereby … <\/p>\n

Continue reading “Eckert & Ziegler to Supply POINT Biopharma with Actinium-225”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-745056","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEckert & Ziegler to Supply POINT Biopharma with Actinium-225 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eckert & Ziegler to Supply POINT Biopharma with Actinium-225 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BERLIN and INDIANAPOLIS, April 04, 2023 (GLOBE NEWSWIRE) — Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (\u201cPOINT\u201d, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225 (non-carrier-added Ac-225). Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT\u2019s pipeline of next generation Ac-225-based radioligands. Actinium-225 is used as an active substance in cancer treatment. The radioisotope emits powerful, high-energy alpha particles with short penetration depths that enable precise treatment of tumor cells with minimal impact on surrounding healthy tissue. For this purpose, Actinium-225 is combined with a suitable carrier (e.g., an antibody or peptide) that specifically binds to cancer cells, thereby … Continue reading "Eckert & Ziegler to Supply POINT Biopharma with Actinium-225"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-04T12:27:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTY1NCM1NTA3MjE5IzIxOTQ1Njg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eckert & Ziegler to Supply POINT Biopharma with Actinium-225\",\"datePublished\":\"2023-04-04T12:27:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\\\/\"},\"wordCount\":609,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMTY1NCM1NTA3MjE5IzIxOTQ1Njg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\\\/\",\"name\":\"Eckert & Ziegler to Supply POINT Biopharma with Actinium-225 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMTY1NCM1NTA3MjE5IzIxOTQ1Njg=\",\"datePublished\":\"2023-04-04T12:27:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMTY1NCM1NTA3MjE5IzIxOTQ1Njg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMTY1NCM1NTA3MjE5IzIxOTQ1Njg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eckert & Ziegler to Supply POINT Biopharma with Actinium-225\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eckert & Ziegler to Supply POINT Biopharma with Actinium-225 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\/","og_locale":"en_US","og_type":"article","og_title":"Eckert & Ziegler to Supply POINT Biopharma with Actinium-225 - Market Newsdesk","og_description":"BERLIN and INDIANAPOLIS, April 04, 2023 (GLOBE NEWSWIRE) — Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (\u201cPOINT\u201d, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225 (non-carrier-added Ac-225). Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT\u2019s pipeline of next generation Ac-225-based radioligands. Actinium-225 is used as an active substance in cancer treatment. The radioisotope emits powerful, high-energy alpha particles with short penetration depths that enable precise treatment of tumor cells with minimal impact on surrounding healthy tissue. For this purpose, Actinium-225 is combined with a suitable carrier (e.g., an antibody or peptide) that specifically binds to cancer cells, thereby … Continue reading \"Eckert & Ziegler to Supply POINT Biopharma with Actinium-225\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-04T12:27:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTY1NCM1NTA3MjE5IzIxOTQ1Njg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eckert & Ziegler to Supply POINT Biopharma with Actinium-225","datePublished":"2023-04-04T12:27:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\/"},"wordCount":609,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTY1NCM1NTA3MjE5IzIxOTQ1Njg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\/","name":"Eckert & Ziegler to Supply POINT Biopharma with Actinium-225 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTY1NCM1NTA3MjE5IzIxOTQ1Njg=","datePublished":"2023-04-04T12:27:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTY1NCM1NTA3MjE5IzIxOTQ1Njg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTY1NCM1NTA3MjE5IzIxOTQ1Njg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eckert-ziegler-to-supply-point-biopharma-with-actinium-225\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eckert & Ziegler to Supply POINT Biopharma with Actinium-225"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/745056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=745056"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/745056\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=745056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=745056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=745056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}